Helix BioPharma Corp.: Helix Biopharma Corp. Announces Fisca

RICHMOND HILL, ON / ACCESSWIRE / December 9, 2021 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field

Related Keywords

New York , United States , Canada , Poland , Toronto , Ontario , Richmond Hill , Ukraine , Canadian , Krzysztof Saczek , Slawomir Majewski , Heman Chao , Drug Administration , Company The Board , Helix Biopharma Corp , Nasdaq , Fund Management , Company Scientific Advisory Board , Company Common , Moffitt Cancer Centre , Toronto Stock Exchange , Company Statement Of Financial Position , Lind Partners , Lind Global Macro Fund , Helix Biopharma , Capital Resources , Lind Agreement , Nasdaq Stock Market , Multijurisdictional Disclosure System , Scientific Advisory Board , Interim Chief Executive Officer , Moffitt Cancer , Common Shares , Each Warrant , Common Share , First Tranche , Convertible Security , Convertible Securities , Funding Agreement , Financial Position , Net Loss , Comprehensive Loss , Looking Statements , Annual Information Form , Helix , Iopharma , Orp , Nnounces , Iscal , 021 , Ear , Results ,